Clinical trialNCT03088878CompletedPhase 1/PHASE2Interventional

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

SponsorOncternal Therapeutics, IncEnrollment95B-cell Chronic Lymphocytic LeukemiaMantle Cell LymphomaMarginal Zone LymphomaSmall Lymphocytic Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Michael Choi, MD
University of California, San Diego
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope (city of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States
Sanford Stem Cell Clinical Center at Ucsd
La Jolla, California, United States
Uc Davis Comprehensive Cancer Center
Sacramento, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Louisiana State University Health New Orleans (nci Community Oncology Research Program)
New Orleans, Louisiana, United States
Hackensack Meridian Health, John Theurer Cancer Center
Hackensack, New Jersey, United States
Northwell Health
New Hyde Park, New York, United States
Columbia University Medical Center
New York, New York, United States
Manhattan Hematology Oncology Research Foundation, Inc.
New York, New York, United States
the Christ Hospital Lindner Research Center
Cincinnati, Ohio, United States
Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cirmtuzumab plus IbrutinibIbrutinib alone

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Jan 2018
Primary completion: 25 Sept 2024
Completion: 25 Sept 2024
Last update posted: 12 Feb 2025
Registered enrollment: 95
Registry id: NCT03088878

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.